Skip to main content
Big Ideas 2024 Is Here! Download Now
Mentioned Companies: CPHD, FMI, GHDX, MYGN

On-site Cancer Tests Can Increase Survival Rates

June 15, 2015
3 min read

Patients with pancreatic cancer have a 35% chance of dying before their molecular diagnostic test results return from the lab. At roughly a 23-29% chance, lung, brain, and stomach cancer patients have only marginally better odds of surviving to see the results, as shown below.

site cancer tests, ARK, ARK Invest, genomics, cancer, diagnostics, on-site testing

ARK Original Research

Precision medicine enables personalized diagnoses and directs molecular treatments. Companies such as Foundation Medicine [FMI], Myriad Genetics [MYGN], and Genomic Health [GHDX] are delivering on this promise using centralized labs, which provide economies of scale and other cost efficiencies.

Because most cancers grow slowly, oncologists have been content with centralized labs. However, while a molecular diagnostic test can inform life or death treatments, patients with high risk cancer types may not live long enough to benefit. After a doctor takes a tumor sample, typically he sends it to a centralized lab for testing. By the time the results are mailed back, often two weeks have been lost.

Alternatively, on-site cancer tests, such as Cepheid’s [CPHD] forthcoming bladder cancer test, should improve patient care. On-site cancer tests will expedite treatment and lower stress, benefitting patients with aggressive forms of cancer particularly.

As companies begin to develop rapid on-site cancer tests, there will be a large total addressable market to serve. High risk patients stand to benefit disproportionately. According to the American Cancer Society, high risk cancers, defined by a cancer that presents patients at least a 20% chance of passing away before a two week lab test returns, are expected to represent 23%, or almost 400,000, of new US cancer diagnoses in 2015 (as shown below).

site cancer tests, ARK, ARK Invest, genomics, cancer, diagnostics, on-site testing


Of high risk cancers in the US, lung cancer poses the greatest threat. More than 221,000 cases will be diagnosed in 2015, three times the 70,000 in brain cancer diagnoses, as shown below.

site cancer tests


Despite the advantages of on-site testing, in the near-term some tests will continue to be done in centralized labs because of their complexity and concomitant costs. While investing in new equipment and training present short-term obstacles, hospitals and urgent care centers that bring same-day on-site testing to oncology will save lives and ultimately gain market share.


You are leaving
By clicking below you acknowledge that you are navigating away from and will be connected to ARK Investment Management LLC manages both web domains. Please take note of ARK’s privacy policy, terms of use, and disclosures that may vary between sites.